|
1
|
Chen MJ, Gatignol A, Scarborough RJ. The discovery and development of RNA-based therapies for treatment of HIV-1 infection. Expert Opin Drug Discov 2023; 18:163-179. [PMID: 36004505 DOI: 10.1080/17460441.2022.2117296] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Long-term control of HIV-1 infection can potentially be achieved using autologous stem cell transplants with gene-modified cells. Non-coding RNAs represent a diverse class of therapeutic agents including ribozymes, RNA aptamers and decoys, small interfering RNAs, short hairpin RNAs, and U1 interference RNAs that can be designed to inhibit HIV-1 replication. They have been engineered for delivery as drugs to complement current HIV-1 therapies and as gene therapies for a potential HIV-1 functional cure. AREAS COVERED This review surveys the past three decades of development of these RNA technologies with a focus on their efficacy and safety for treating HIV-1 infections. We describe the mechanisms of each RNA-based agent, targets they have been developed against, efforts to enhance their stability and efficacy, and we evaluate their performance in past and ongoing preclinical and clinical trials. EXPERT OPINION RNA-based technologies are among the top candidates for gene therapies where they can be stably expressed for long-term suppression of HIV-1. Advances in both gene and drug delivery strategies and improvements to non-coding RNA stability and antiviral properties will cooperatively drive forward progress in improving drug therapy and engineering HIV-1 resistant cells.
Collapse
Affiliation(s)
- Michelle J Chen
- Lady Davis Institute for Medical Research, Montréal, Québec, Canada.,Department of Medicine, Division of Experimental Medicine, McGill University, Montréal, Québec, Canada
| | - Anne Gatignol
- Lady Davis Institute for Medical Research, Montréal, Québec, Canada.,Department of Medicine, Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.,Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada
| | - Robert J Scarborough
- Lady Davis Institute for Medical Research, Montréal, Québec, Canada.,Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada
| |
Collapse
|
|
2
|
Liang Z, Su D, Liu K, Jiang H. Comprehensive analysis of molecular mechanism and a novel prognostic signature based on small nuclear RNA biomarkers in gastric cancer patients. Open Med (Wars) 2022; 17:991-1006. [PMID: 35733621 PMCID: PMC9164292 DOI: 10.1515/med-2022-0493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 04/17/2022] [Accepted: 04/28/2022] [Indexed: 11/24/2022] Open
Abstract
Small nuclear RNAs (snRNAs) are rarely reported in cancer. This study is based on The Cancer Genome Atlas genome-wide data set to explore the prognostic value and molecular mechanism of snRNAs in gastric cancer (GC). Gene ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analysis were used to explore the molecular mechanism of snRNAs. A total of 351 patients were included in the survival analysis, and 14 prognostic snRNAs were identified using multivariate survival analysis. We constructed a prognostic signature containing nine snRNAs, which can signally classify patients into high- and low-risk phenotypes (adjusted P < 0.0001, hazard ratio = 2.671, 95% confidence interval = 1.850–3.858). Combining the molecular mechanisms obtained by the three functional enrichment approaches, we concluded that this prognostic signature snRNAs participated in classical tumor-related signaling pathways, including Notch, PI3K, toll-like receptor, etc.; cell adhesion; cell cycle; cell proliferation; and other biological processes that affect the biological phenotype of cancer cells. We also found significant downregulation of the abundance of immune cell infiltrates and immune microenvironment scores for high-risk phenotypes of GC patients. In conclusion, this study has identified 14 prognostic snRNAs signally associated with GC overall survival and also constructed a novel prognostic signature containing nine prognostic snRNAs.
Collapse
Affiliation(s)
- Ziyu Liang
- Department of Gastroenterology, The Third Affiliated Hospital of Guangxi Medical University , Nanning , 530000, Guangxi Zhuang Autonomous Region , People’s Republic of China
| | - Dongxing Su
- Department of Gastroenterology, The Third Affiliated Hospital of Guangxi Medical University , Nanning , 530000, Guangxi Zhuang Autonomous Region , People’s Republic of China
| | - Kang Liu
- Department of Radiation Oncology , The First Affiliated Hospital of Guangxi Medical University , Nanning , 530021, Guangxi Zhuang Autonomous Region , People’s Republic of China
| | - Haixing Jiang
- Department of Gastroenterology , The First Affiliated Hospital of Guangxi Medical University , Shuang Yong Road 6 , Nanning , 530021, Guangxi Zhuang Autonomous Region , People’s Republic of China
| |
Collapse
|
|
3
|
Sergeeva OV, Shcherbinina EY, Shomron N, Zatsepin TS. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications. Nucleic Acid Ther 2022; 32:123-138. [PMID: 35166605 DOI: 10.1089/nat.2021.0067] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Dysregulation of RNA splicing causes many diseases and disorders. Several therapeutic approaches have been developed to correct aberrant alternative splicing events for the treatment of cancers and hereditary diseases, including gene therapy and redirecting splicing, using small molecules or splice switching oligonucleotides (SSO). Significant advances in the chemistry and pharmacology of nucleic acid have led to the development of clinically approved SSO drugs for the treatment of spinal muscular dystrophy and Duchenne muscular dystrophy (DMD). In this review, we discuss the mechanisms of SSO action with emphasis on "less common" approaches to modulate alternative splicing, including bipartite and bifunctional SSO, oligonucleotide decoys for splice factors and SSO-mediated mRNA degradation via AS-NMD and NGD pathways. We briefly discuss the current progress and future perspectives of SSO therapy for rare and ultrarare diseases.
Collapse
Affiliation(s)
- Olga V Sergeeva
- Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia
| | | | - Noam Shomron
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Timofei S Zatsepin
- Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia.,Department of Chemistry, Moscow State University, Moscow, Russia
| |
Collapse
|
|
4
|
Seifert C, Balz E, Herzog S, Korolev A, Gaßmann S, Paland H, Fink MA, Grube M, Marx S, Jedlitschky G, Tzvetkov MV, Rauch BH, Schroeder HWS, Bien-Möller S. PIM1 Inhibition Affects Glioblastoma Stem Cell Behavior and Kills Glioblastoma Stem-like Cells. Int J Mol Sci 2021; 22:ijms222011126. [PMID: 34681783 PMCID: PMC8541331 DOI: 10.3390/ijms222011126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/05/2021] [Accepted: 10/09/2021] [Indexed: 12/15/2022] Open
Abstract
Despite comprehensive therapy and extensive research, glioblastoma (GBM) still represents the most aggressive brain tumor in adults. Glioma stem cells (GSCs) are thought to play a major role in tumor progression and resistance of GBM cells to radiochemotherapy. The PIM1 kinase has become a focus in cancer research. We have previously demonstrated that PIM1 is involved in survival of GBM cells and in GBM growth in a mouse model. However, little is known about the importance of PIM1 in cancer stem cells. Here, we report on the role of PIM1 in GBM stem cell behavior and killing. PIM1 inhibition negatively regulates the protein expression of the stem cell markers CD133 and Nestin in GBM cells (LN-18, U-87 MG). In contrast, CD44 and the astrocytic differentiation marker GFAP were up-regulated. Furthermore, PIM1 expression was increased in neurospheres as a model of GBM stem-like cells. Treatment of neurospheres with PIM1 inhibitors (TCS PIM1-1, Quercetagetin, and LY294002) diminished the cell viability associated with reduced DNA synthesis rate, increased caspase 3 activity, decreased PCNA protein expression, and reduced neurosphere formation. Our results indicate that PIM1 affects the glioblastoma stem cell behavior, and its inhibition kills glioblastoma stem-like cells, pointing to PIM1 targeting as a potential anti-glioblastoma therapy.
Collapse
Affiliation(s)
- Carolin Seifert
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Ellen Balz
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Susann Herzog
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Anna Korolev
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Sebastian Gaßmann
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Heiko Paland
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Matthias A. Fink
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Markus Grube
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Sascha Marx
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Gabriele Jedlitschky
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Mladen V. Tzvetkov
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
| | - Bernhard H. Rauch
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Pharmacology and Toxicology, Carl von Ossietzky University Oldenburg, 26129 Oldenburg, Germany
| | - Henry W. S. Schroeder
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
| | - Sandra Bien-Möller
- Department of Pharmacology, University Medicine Greifswald, 17489 Greifswald, Germany; (C.S.); (E.B.); (S.H.); (A.K.); (S.G.); (H.P.); (M.A.F.); (M.G.); (G.J.); (M.V.T.); (B.H.R.)
- Department of Neurosurgery, University Medicine Greifswald, 17489 Greifswald, Germany; (S.M.); (H.W.S.S.)
- Correspondence: ; Tel.: +49-03834-865646
| |
Collapse
|
|
5
|
Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth. Cancers (Basel) 2020; 12:cancers12092707. [PMID: 32967361 PMCID: PMC7564455 DOI: 10.3390/cancers12092707] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 09/16/2020] [Accepted: 09/17/2020] [Indexed: 11/17/2022] Open
Abstract
Simple Summary Glioblastomas are very malignant and essentially incurable brain tumors. One problem is the extensive penetration of tumor cells into the adjacent normal brain tissue. Thus, the testing of novel drugs requires appropriate tumor models, preferentially avoiding animal studies. This paper describes so-called brain tissue slice tandem-culture systems. They consist of a slice of normal brain tissue and a second layer of tumor tissue. The microscopic analysis of these slice tandem-cultures allows for the simultaneous assessment of single cells invading into the normal brain tissue and the space occupying growth of the total tumor mass. It is shown that the direct application of test drugs onto the slices exerts inhibitory effects on both mechanisms. We thus describe a system mimicking the situation in glioblastoma patients. It reduces animal studies, allows for the direct application of test drugs and the precise quantitation of their inhibitory effects on tumor growth and invasion. Abstract Glioblastomas (GBMs) are the most malignant brain tumors and are essentially incurable even after extensive surgery, radiotherapy, and chemotherapy, mainly because of extensive infiltration of tumor cells into the adjacent normal tissue. Thus, the evaluation of novel drugs in malignant glioma treatment requires sophisticated ex vivo models that approach the authentic interplay between tumor and host environment while avoiding extensive in vivo studies in animals. This paper describes the standardized setup of an organotypic brain tissue slice tandem-culture system, comprising of normal brain tissue from adult mice and tumor tissue from human glioblastoma xenografts, and explore its utility for assessing inhibitory effects of test drugs. The microscopic analysis of vertical sections of the slice tandem-cultures allows for the simultaneous assessment of (i) the invasive potential of single cells or cell aggregates and (ii) the space occupying growth of the bulk tumor mass, both contributing to malignant tumor progression. The comparison of tissue slice co-cultures with spheroids vs. tissue slice tandem-cultures using tumor xenograft slices demonstrates advantages of the xenograft tandem approach. The direct and facile application of test drugs is shown to exert inhibitory effects on bulk tumor growth and/or tumor cell invasion, and allows their precise quantitation. In conclusion, we describe a straightforward ex vivo system mimicking the in vivo situation of the tumor mass and the normal brain in GBM patients. It reduces animal studies and allows for the direct and reproducible application of test drugs and the precise quantitation of their effects on the bulk tumor mass and on the tumor’s invasive properties.
Collapse
|
|
6
|
Tsang AT, Dudgeon C, Yi L, Yu X, Goraczniak R, Donohue K, Kogan S, Brenneman MA, Ho ES, Gunderson SI, Carpizo DR. U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts. Mol Cancer Ther 2017; 16:1445-1455. [PMID: 28377488 DOI: 10.1158/1535-7163.mct-16-0867] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 03/13/2017] [Accepted: 03/27/2017] [Indexed: 12/25/2022]
Abstract
Targeting KRAS and MYC has been a tremendous challenge in cancer drug development. Genetic studies in mouse models have validated the efficacy of silencing expression of both KRAS and MYC in mutant KRAS-driven tumors. We investigated the therapeutic potential of a new oligonucleotide-mediated gene silencing technology (U1 Adaptor) targeting KRAS and MYC in pancreatic cancer. Nanoparticles in complex with anti-KRAS U1 Adaptors (U1-KRAS) showed remarkable inhibition of KRAS in different human pancreatic cancer cell lines in vitro and in vivo As a nanoparticle-free approach is far easier to develop into a drug, we refined the formulation of U1 Adaptors by conjugating them to tumor-targeting peptides (iRGD and cRGD). Peptides coupled to fluorescently tagged U1 Adaptors showed selective tumor localization in vivo Efficacy experiments in pancreatic cancer xenograft models showed highly potent (>90%) antitumor activity of both iRGD and (cRGD)2-KRAS Adaptors. U1 Adaptors targeting MYC inhibited pancreatic cancer cell proliferation caused by apoptosis in vitro (40%-70%) and tumor regressions in vivo Comparison of iRGD-conjugated U1 KRAS and U1 MYC Adaptors in vivo revealed a significantly greater degree of cleaved caspase-3 staining and decreased Ki67 staining as compared with controls. There was no significant difference in efficacy between the U1 KRAS and U1 MYC Adaptor groups. Our results validate the value in targeting both KRAS and MYC in pancreatic cancer therapeutics and provide evidence that the U1 Adaptor technology can be successfully translated using a nanoparticle-free delivery system to target two undruggable genes in cancer. Mol Cancer Ther; 16(8); 1445-55. ©2017 AACR.
Collapse
Affiliation(s)
- Ashley T Tsang
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | - Crissy Dudgeon
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | - Lan Yi
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | - Xin Yu
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | | | - Kristen Donohue
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
| | - Samuel Kogan
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.,Department of Pharmacology, Rutgers University, Piscataway, New Jersey
| | | | - Eric S Ho
- Department of Biology, Lafayette College, Easton, Pennsylvania
| | - Samuel I Gunderson
- Silagene Inc., Hillsborough, New Jersey.,Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey
| | - Darren R Carpizo
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. .,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.,Department of Pharmacology, Rutgers University, Piscataway, New Jersey
| |
Collapse
|
|
7
|
Pelaz B, Alexiou C, Alvarez-Puebla RA, Alves F, Andrews AM, Ashraf S, Balogh LP, Ballerini L, Bestetti A, Brendel C, Bosi S, Carril M, Chan WCW, Chen C, Chen X, Chen X, Cheng Z, Cui D, Du J, Dullin C, Escudero A, Feliu N, Gao M, George M, Gogotsi Y, Grünweller A, Gu Z, Halas NJ, Hampp N, Hartmann RK, Hersam MC, Hunziker P, Jian J, Jiang X, Jungebluth P, Kadhiresan P, Kataoka K, Khademhosseini A, Kopeček J, Kotov NA, Krug HF, Lee DS, Lehr CM, Leong KW, Liang XJ, Ling Lim M, Liz-Marzán LM, Ma X, Macchiarini P, Meng H, Möhwald H, Mulvaney P, Nel AE, Nie S, Nordlander P, Okano T, Oliveira J, Park TH, Penner RM, Prato M, Puntes V, Rotello VM, Samarakoon A, Schaak RE, Shen Y, Sjöqvist S, Skirtach AG, Soliman MG, Stevens MM, Sung HW, Tang BZ, Tietze R, Udugama BN, VanEpps JS, Weil T, Weiss PS, Willner I, Wu Y, Yang L, Yue Z, Zhang Q, Zhang Q, Zhang XE, Zhao Y, Zhou X, Parak WJ. Diverse Applications of Nanomedicine. ACS NANO 2017; 11:2313-2381. [PMID: 28290206 PMCID: PMC5371978 DOI: 10.1021/acsnano.6b06040] [Citation(s) in RCA: 775] [Impact Index Per Article: 110.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Indexed: 04/14/2023]
Abstract
The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic.
Collapse
Affiliation(s)
- Beatriz Pelaz
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Christoph Alexiou
- ENT-Department, Section of Experimental Oncology & Nanomedicine
(SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Ramon A. Alvarez-Puebla
- Department of Physical Chemistry, Universitat Rovira I Virgili, 43007 Tarragona, Spain
- ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain
| | - Frauke Alves
- Department of Haematology and Medical Oncology, Department of Diagnostic
and Interventional Radiology, University
Medical Center Göttingen, 37075 Göttingen Germany
- Department of Molecular Biology of Neuronal Signals, Max-Planck-Institute for Experimental Medicine, 37075 Göttingen, Germany
| | - Anne M. Andrews
- California NanoSystems Institute, Department of Chemistry
and Biochemistry and Department of Psychiatry and Semel Institute
for Neuroscience and Human Behavior, Division of NanoMedicine and Center
for the Environmental Impact of Nanotechnology, and Department of Materials Science
and Engineering, University of California,
Los Angeles, Los Angeles, California 90095, United States
| | - Sumaira Ashraf
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Lajos P. Balogh
- AA Nanomedicine & Nanotechnology Consultants, North Andover, Massachusetts 01845, United States
| | - Laura Ballerini
- International School for Advanced Studies (SISSA/ISAS), 34136 Trieste, Italy
| | - Alessandra Bestetti
- School of Chemistry & Bio21 Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Cornelia Brendel
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Susanna Bosi
- Department of Chemical
and Pharmaceutical Sciences, University
of Trieste, 34127 Trieste, Italy
| | - Monica Carril
- CIC biomaGUNE, Paseo de Miramón 182, 20014, Donostia - San Sebastián, Spain
- Ikerbasque, Basque Foundation
for Science, 48013 Bilbao, Spain
| | - Warren C. W. Chan
- Institute of Biomaterials
and Biomedical Engineering, University of
Toronto, Toronto, Ontario M5S 3G9, Canada
| | - Chunying Chen
- CAS Center for Excellence in Nanoscience and CAS Key
Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of
China, Beijing 100190, China
| | - Xiaodong Chen
- School of Materials
Science and Engineering, Nanyang Technological
University, Singapore 639798
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine,
National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Zhen Cheng
- Molecular
Imaging Program at Stanford and Bio-X Program, Canary Center at Stanford
for Cancer Early Detection, Stanford University, Stanford, California 94305, United States
| | - Daxiang Cui
- Institute of Nano Biomedicine and Engineering, Department of Instrument
Science and Engineering, School of Electronic Information and Electronical
Engineering, National Center for Translational Medicine, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Jianzhong Du
- Department of Polymeric Materials, School of Materials
Science and Engineering, Tongji University, Shanghai, China
| | - Christian Dullin
- Department of Haematology and Medical Oncology, Department of Diagnostic
and Interventional Radiology, University
Medical Center Göttingen, 37075 Göttingen Germany
| | - Alberto Escudero
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
- Instituto
de Ciencia de Materiales de Sevilla. CSIC, Universidad de Sevilla, 41092 Seville, Spain
| | - Neus Feliu
- Department of Clinical Science, Intervention, and Technology (CLINTEC), Karolinska Institutet, 141 86 Stockholm, Sweden
| | - Mingyuan Gao
- Institute of Chemistry, Chinese
Academy of Sciences, 100190 Beijing, China
| | | | - Yury Gogotsi
- Department of Materials Science and Engineering and A.J. Drexel Nanomaterials
Institute, Drexel University, Philadelphia, Pennsylvania 19104, United States
| | - Arnold Grünweller
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Zhongwei Gu
- College of Polymer Science and Engineering, Sichuan University, 610000 Chengdu, China
| | - Naomi J. Halas
- Departments of Physics and Astronomy, Rice
University, Houston, Texas 77005, United
States
| | - Norbert Hampp
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Roland K. Hartmann
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Mark C. Hersam
- Departments of Materials Science and Engineering, Chemistry,
and Medicine, Northwestern University, Evanston, Illinois 60208, United States
| | - Patrick Hunziker
- University Hospital, 4056 Basel, Switzerland
- CLINAM,
European Foundation for Clinical Nanomedicine, 4058 Basel, Switzerland
| | - Ji Jian
- Department of Polymer Science and Engineering and Center for
Bionanoengineering and Department of Chemical and Biological Engineering, Zhejiang University, 310027 Hangzhou, China
| | - Xingyu Jiang
- CAS Center for Excellence in Nanoscience and CAS Key
Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of
China, Beijing 100190, China
| | - Philipp Jungebluth
- Thoraxklinik Heidelberg, Universitätsklinikum
Heidelberg, 69120 Heidelberg, Germany
| | - Pranav Kadhiresan
- Institute of Biomaterials
and Biomedical Engineering, University of
Toronto, Toronto, Ontario M5S 3G9, Canada
| | | | | | - Jindřich Kopeček
- Biomedical Polymers Laboratory, University of Utah, Salt Lake City, Utah 84112, United States
| | - Nicholas A. Kotov
- Emergency Medicine, University of Michigan, Ann Arbor, Michigan 48019, United States
| | - Harald F. Krug
- EMPA, Federal Institute for Materials
Science and Technology, CH-9014 St. Gallen, Switzerland
| | - Dong Soo Lee
- Department of Molecular Medicine and Biopharmaceutical
Sciences and School of Chemical and Biological Engineering, Seoul National University, Seoul, South Korea
| | - Claus-Michael Lehr
- Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany
- HIPS - Helmhotz Institute for Pharmaceutical Research Saarland, Helmholtz-Center for Infection Research, 66123 Saarbrücken, Germany
| | - Kam W. Leong
- Department of Biomedical Engineering, Columbia University, New York City, New York 10027, United States
| | - Xing-Jie Liang
- CAS Center for Excellence in Nanoscience and CAS Key
Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of
China, Beijing 100190, China
- Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences (CAS), 100190 Beijing, China
| | - Mei Ling Lim
- Department of Clinical Science, Intervention, and Technology (CLINTEC), Karolinska Institutet, 141 86 Stockholm, Sweden
| | - Luis M. Liz-Marzán
- CIC biomaGUNE, Paseo de Miramón 182, 20014, Donostia - San Sebastián, Spain
- Ikerbasque, Basque Foundation
for Science, 48013 Bilbao, Spain
- Biomedical Research Networking Center in Bioengineering Biomaterials and Nanomedicine, Ciber-BBN, 20014 Donostia - San Sebastián, Spain
| | - Xiaowei Ma
- Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences (CAS), 100190 Beijing, China
| | - Paolo Macchiarini
- Laboratory of Bioengineering Regenerative Medicine (BioReM), Kazan Federal University, 420008 Kazan, Russia
| | - Huan Meng
- California NanoSystems Institute, Department of Chemistry
and Biochemistry and Department of Psychiatry and Semel Institute
for Neuroscience and Human Behavior, Division of NanoMedicine and Center
for the Environmental Impact of Nanotechnology, and Department of Materials Science
and Engineering, University of California,
Los Angeles, Los Angeles, California 90095, United States
| | - Helmuth Möhwald
- Department of Interfaces, Max-Planck
Institute of Colloids and Interfaces, 14476 Potsdam, Germany
| | - Paul Mulvaney
- School of Chemistry & Bio21 Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Andre E. Nel
- California NanoSystems Institute, Department of Chemistry
and Biochemistry and Department of Psychiatry and Semel Institute
for Neuroscience and Human Behavior, Division of NanoMedicine and Center
for the Environmental Impact of Nanotechnology, and Department of Materials Science
and Engineering, University of California,
Los Angeles, Los Angeles, California 90095, United States
| | - Shuming Nie
- Emory University, Atlanta, Georgia 30322, United States
| | - Peter Nordlander
- Departments of Physics and Astronomy, Rice
University, Houston, Texas 77005, United
States
| | - Teruo Okano
- Tokyo Women’s Medical University, Tokyo 162-8666, Japan
| | | | - Tai Hyun Park
- Department of Molecular Medicine and Biopharmaceutical
Sciences and School of Chemical and Biological Engineering, Seoul National University, Seoul, South Korea
- Advanced Institutes of Convergence Technology, Suwon, South Korea
| | - Reginald M. Penner
- Department of Chemistry, University of
California, Irvine, California 92697, United States
| | - Maurizio Prato
- Department of Chemical
and Pharmaceutical Sciences, University
of Trieste, 34127 Trieste, Italy
- CIC biomaGUNE, Paseo de Miramón 182, 20014, Donostia - San Sebastián, Spain
- Ikerbasque, Basque Foundation
for Science, 48013 Bilbao, Spain
| | - Victor Puntes
- ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain
- Institut Català de Nanotecnologia, UAB, 08193 Barcelona, Spain
- Vall d’Hebron University Hospital
Institute of Research, 08035 Barcelona, Spain
| | - Vincent M. Rotello
- Department
of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States
| | - Amila Samarakoon
- Institute of Biomaterials
and Biomedical Engineering, University of
Toronto, Toronto, Ontario M5S 3G9, Canada
| | - Raymond E. Schaak
- Department of Chemistry, The
Pennsylvania State University, University Park, Pennsylvania 16802, United States
| | - Youqing Shen
- Department of Polymer Science and Engineering and Center for
Bionanoengineering and Department of Chemical and Biological Engineering, Zhejiang University, 310027 Hangzhou, China
| | - Sebastian Sjöqvist
- Department of Clinical Science, Intervention, and Technology (CLINTEC), Karolinska Institutet, 141 86 Stockholm, Sweden
| | - Andre G. Skirtach
- Department of Interfaces, Max-Planck
Institute of Colloids and Interfaces, 14476 Potsdam, Germany
- Department of Molecular Biotechnology, University of Ghent, B-9000 Ghent, Belgium
| | - Mahmoud G. Soliman
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Molly M. Stevens
- Department of Materials,
Department of Bioengineering, Institute for Biomedical Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - Hsing-Wen Sung
- Department of Chemical Engineering and Institute of Biomedical
Engineering, National Tsing Hua University, Hsinchu City, Taiwan,
ROC 300
| | - Ben Zhong Tang
- Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Hong Kong, China
| | - Rainer Tietze
- ENT-Department, Section of Experimental Oncology & Nanomedicine
(SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Buddhisha N. Udugama
- Institute of Biomaterials
and Biomedical Engineering, University of
Toronto, Toronto, Ontario M5S 3G9, Canada
| | - J. Scott VanEpps
- Emergency Medicine, University of Michigan, Ann Arbor, Michigan 48019, United States
| | - Tanja Weil
- Institut für
Organische Chemie, Universität Ulm, 89081 Ulm, Germany
- Max-Planck-Institute for Polymer Research, 55128 Mainz, Germany
| | - Paul S. Weiss
- California NanoSystems Institute, Department of Chemistry
and Biochemistry and Department of Psychiatry and Semel Institute
for Neuroscience and Human Behavior, Division of NanoMedicine and Center
for the Environmental Impact of Nanotechnology, and Department of Materials Science
and Engineering, University of California,
Los Angeles, Los Angeles, California 90095, United States
| | - Itamar Willner
- Institute of Chemistry, The Center for
Nanoscience and Nanotechnology, The Hebrew
University of Jerusalem, Jerusalem 91904, Israel
| | - Yuzhou Wu
- Max-Planck-Institute for Polymer Research, 55128 Mainz, Germany
- School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, 430074 Wuhan, China
| | | | - Zhao Yue
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Qian Zhang
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
| | - Qiang Zhang
- School of Pharmaceutical Science, Peking University, 100191 Beijing, China
| | - Xian-En Zhang
- National Laboratory of Biomacromolecules,
CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing, 100101, China
| | - Yuliang Zhao
- CAS Center for Excellence in Nanoscience and CAS Key
Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of
China, Beijing 100190, China
| | - Xin Zhou
- Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan 430071, China
| | - Wolfgang J. Parak
- Fachbereich Physik, Fachbereich Medizin, Fachbereich Pharmazie, and Department of Chemistry, Philipps Universität Marburg, 35037 Marburg, Germany
- CIC biomaGUNE, Paseo de Miramón 182, 20014, Donostia - San Sebastián, Spain
| |
Collapse
|
|
8
|
Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, Miletic H, Hildner M, Fritsch M, Vogelgesang S, Havemann C, Ritter CA, Meyer zu Schwabedissen HE, Rauch B, Hoffmann W, Kroemer HK, Schroeder H, Bien-Möller S. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro Oncol 2014; 17:223-42. [PMID: 25155357 DOI: 10.1093/neuonc/nou216] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND The current therapy for glioblastoma multiforme (GBM), the most aggressive and common primary brain tumor of adults, involves surgery and a combined radiochemotherapy that controls tumor progression only for a limited time window. Therefore, the identification of new molecular targets is highly necessary. Inhibition of kinases has become a standard of clinical oncology, and thus the oncogenic kinase Pim1 might represent a promising target for improvement of GBM therapy. METHODS Expression of Pim1 and associated signaling molecules was analyzed in human GBM samples, and the potential role of this kinase in patients' prognosis was evaluated. Furthermore, we analyzed the in vivo role of Pim1 in GBM cell growth in an orthotopic mouse model and examined the consequences of Pim1 inhibition in vitro to clarify underlying pathways. RESULTS In comparison with normal brain, a strong upregulation of Pim1 was demonstrated in human GBM samples. Notably, patients with short overall survival showed a significantly higher Pim1 expression compared with GBM patients who lived longer than the median. In vitro experiments with GBM cells and analysis of patients' GBM samples suggest that Pim1 regulation is dependent on epidermal growth factor receptor. Furthermore, inhibition of Pim1 resulted in reduced cell viability accompanied by decreased cell numbers and increased apoptotic cells, as seen by elevated subG1 cell contents and caspase-3 and -9 activation, as well as modulation of several cell cycle or apoptosis regulatory proteins. CONCLUSIONS Altogether, Pim1 could be a novel therapeutic target, which should be further analyzed to improve the outcome of patients with aggressive GBM.
Collapse
Affiliation(s)
- Susann Herzog
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Matthias Alexander Fink
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Kerstin Weitmann
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Claudius Friedel
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Stefan Hadlich
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Sönke Langner
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Katharina Kindermann
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Tobias Holm
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Andreas Böhm
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Eskil Eskilsson
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Hrvoje Miletic
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Markus Hildner
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Michael Fritsch
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Silke Vogelgesang
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Christoph Havemann
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Christoph Alexander Ritter
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Henriette Elisabeth Meyer zu Schwabedissen
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Bernhard Rauch
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Wolfgang Hoffmann
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Heyo Klaus Kroemer
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Henry Schroeder
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| | - Sandra Bien-Möller
- Department of Pharmacology/C_DAT (S.H., M.H., M.A.F., T.H., A.B., H.E.M.z.S., H.K.K., B.R., S.B-M.); Institute of Pathology (S.V.); Institute of Pharmacy (C.A.R.); Institute for Community Medicine (K.W., C.H., W.H.); Clinic of Neurosurgery (C.F., M.F., H.S.); Institute of Radiology and Neuroradiology, Universitätsmedizin Greifswald, Greifswald, Germany (S.H., K.K., S.L.); Department of Biomedicine, University of Bergen, Bergen, Norway (E.E., H.M.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (E.E., H.M.)
| |
Collapse
|
|
9
|
U1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer. Int J Cell Biol 2013; 2013:846510. [PMID: 24285958 PMCID: PMC3826338 DOI: 10.1155/2013/846510] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Accepted: 09/05/2013] [Indexed: 11/17/2022] Open
Abstract
Pre-mRNA splicing and polyadenylation are critical steps in the maturation of eukaryotic mRNA. U1 snRNP is an essential component of the splicing machinery and participates in splice-site selection and spliceosome assembly by base-pairing to the 5' splice site. U1 snRNP also plays an additional, nonsplicing global function in 3' end mRNA processing; it actively suppresses the polyadenylation machinery from using early, mostly intronic polyadenylation signals which would lead to aberrant, truncated mRNAs. Thus, U1 snRNP safeguards pre-mRNA transcripts against premature polyadenylation and contributes to the regulation of alternative polyadenylation. Here, we review the role of U1 snRNP in 3' end mRNA processing, outline the evidence that led to the recognition of its physiological, general role in inhibiting polyadenylation, and finally highlight the possibility of manipulating this U1 snRNP function for therapeutic purposes in cancer.
Collapse
|